Return to CG181 Overview

Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]

Measuring the use of this guidance

Recommendation: 1.3.18

Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10‑year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.

What was measured: CVD-PP001: In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins.
Data collection end: March 2015
67.7%
Data collection end: March 2017
65.9%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.

What was measured: Proportion of patients in Wales between May 2008 and December 2014 prescribed a statin for primary prevention of CVD who were prescribed atorvastatin.
Data collection end: December 2014
8%
Area covered: Wales
Source: Protty Majd B, Lacey Arron, Hayes Jamie, and Freeman Phillip. (2016). Statins for primary prevention in practice: clinical use in Wales and the NICE guideline effect. British journal of clinical pharmacology, 82(3), pp.892-4.

What was measured: CVD-PP001: In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins.
Data collection end: March 2016
66.5%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.


Recommendation: 1.3.27

Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD[7]

What was measured: Proportion of people with known CKD who were prescribed statins
Data collection end: June 2016
68.8%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.


Recommendation: 1.7.8

If not already measured, check the haemoglobin level in people with a GFR of less than 45 ml/min/1.73 m2 (GFR category G3b, G4 or G5) to identify anaemia (haemoglobin less than 110 g/litre [11.0 g/dl], see Anaemia management in people with chronic kidney disease [NICE guideline CG114]). Determine the subsequent frequency of testing by the measured value and the clinical circumstances. [2008]

What was measured: Proportion of people who had an eGFR<45ml/min who were recorded as having a haemoglobin blood test to screen for renal anaemia
Data collection end: June 2016
73.9%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.



 Return to CG181 Overview